Background and Aim: The diagnosis of celiac disease autoimmune pathology relies on the subjective histological assignment of biopsies into Marsh score categories. It is hypothesized that Marsh score categories have unique gene expression signatures. The aims were as follows: first, to develop a celiac disease quantitative reverse transcription-polymerase chain reaction (RT-PCR) array; second, define gene expression signatures associated with Marsh score categories; and third, develop equations that classify biopsies into Marsh score categories and to monitor the efficacy of patient treatment. Methods: Gene targets for inclusion in the celiac RT-PCR (qRT-PCR) array were identified using systematic analysis of published celiac transcriptomic data. The array was used to assess the gene expression associated with histological changes in duodenal biopsies obtained from adult patients. Finally, Marsh score classification equations were defined using discriminant analysis. Results: The array contained 87 genes. The expression of 26 genes were significantly (p < 0.06) associated with the discrete Marsh score categories. As the Marsh score pathology of biopsies increased, there was a progression of innate immune gene expression through adaptive Th1-specific gene expression with a concurrent decrease in intestinal structural gene expression in high Marsh score samples. These 26 genes were used to define classification equations that accounted for 99% of the observed experimental variation and which could classify biopsies into Marsh score categories and monitor patient treatment progression. Conclusions: This proof-of-concept study successfully developed a celiac RT-PCR array and has provided evidence that discriminant equations defined using gene expression data can objectively and accurately classify duodenal biopsies into Marsh score categories.
Introduction
Celiac disease (CD) is an autoimmune enteropathy against gluten epitopes, a protein found in grains. 1, 2 Currently, approximately 1% of the population of the USA and Europe has been diagnosed with CD, 3 and it has been shown that complications can occur if CD is left untreated for long periods, including an increased risk of malignancy. 4 The diagnosis of CD is primarily based on histological assessment of the structure of the intestine, which is graded using the Marsh score scale, which contains four categories from M0 (normal tissue structure) to active CD (M3), which is characterized by villous atrophy. 5 A subclassification of the original M3 Marsh score suggested by Oberhuber et al. 6 further subdivided active CD according to the degree of villous atrophy observed, that is, stage 3a represents partial villous atrophy, 3b represents subtotal villous atrophy, and 3c represents total villous atrophy.
Misdiagnosis of CD severity may occur due to the subjective interpretation of biopsy material, particularly for patients presenting with mild or equivocal pathology. This may lead to negative or delayed patient outcomes. [5] [6] [7] [8] Therefore, several studies have attempted to improve the objectivity of Marsh diagnosis by using discriminant equations to classify patient biopsies. For example, data from IgA/IgG serology, 9, 10 intraepithelial lymphocyte counts with crypt/villous ratios, 11 immunohistochemistry data, 12 quantitative analysis of capsule endoscopy images, 13 and biopsy histological analysis 14 have been used to define classification equations. However, these studies were only able to define low-resolution classification equations capable of discriminating healthy from pathological tissues. Therefore, in order to define higher resolution predictive Marsh score equations, it is suggested that non-histological parameters are required. Since gene (protein) expression determines the physiological structure and function of a tissue, it is hypothesized that tissue gene expression perturbations are associated with the severity of CD observed in patients and can therefore be used to objectively classify the severity of CD. Thus, this study describes the development of a quantitative RT-PCR CD array, which was used to quantify the expression of genes associated with Marsh score categories.
Methods
Sample biopsies. This study was reviewed by the appropriate ethics committee and was performed in accordance with the ethical standards laid down by the Declaration of Helsinki (2013). All patients gave written, informed consent prior to their inclusion in the study (approval number HE13-184). Thirty female and six male patients (mean age 48.6 ± 16.7 years; range 19-82 years) were recruited into the study.
Subjects with no specific duodenal pathology (n = 14) were used as normal controls. Serologically positive CD patients (n = 16) were further divided histologically into the relevant Marsh score categories. The examining independent histopathologist (working at a commercial pathology laboratory) was blinded to the current study however and to previous work.
14 Histological diagnosis was then confirmed in-house using routine H&E staining (with a CD cut-off of 25 intraepithelial lymphocytes/100 enterocytes). A number of patients (n = 4) being treated for CD with a gluten-free diet were also included in the study with their follow-up biopsies. Two patients provided both an initial biopsy and follow-up biopsy after treatment. Details of treated CD patients is included in Table 1 . All patients newly diagnosed with CD had been on a gluten-containing diet at the time of biopsy as per the current clinical guidelines.
Proximal duodenal biopsies (from D2) were collected from all patients during routine gastroscopic examination and were fixed for histological analysis or were collected into RNAlater (Qiagen, Venlo, The Netherlands) and archived at À20°C until required.
Selection of genes for the celiac disease quantitative reverse transcription-polymerase chain reaction array. A systematic analysis of CD microarray or RT-PCR studies from patients with Marsh scores 1-3b and serologically positive and normal control subjects [15] [16] [17] [18] [19] [20] [21] was conducted to identify candidate genes for the CD qRT-PCR array.
Differential gene expression analysis was performed by using ToppGene. 22 Expression networks of significantly differentially expressed genes (CD: healthy control) were visualized using Cytoscape v4.1.0. 23 Gene ontology analysis was performed using BiNGO 24 and ClueGO v2.1.1 25 to determine significantly enriched ontological pathways associated with CD.
RNA isolation and cDNA synthesis. Total RNA was extracted from patient duodenal biopsy material using an Aurum Total RNA Mini Kit (Biorad, Hercules, CA, USA). Genomic DNA contamination of the RNA preparation was digested using a TURBO DNA-free kit (Thermo Fisher Scientific, Waltham, MA, USA). RNA quality was monitored by 1% agarose gel electrophoresis, and the concentration was determined using a Nanodrop 8000 (Thermo Fisher Scientific, Waltham, MA, USA). Total RNA was reverse transcribed into cDNA using the iScript cDNA synthesis kit (BioRad, USA).
Celiac disease quantitative reverse transcriptionpolymerase chain reaction array construction. Validated primer pairs for each human gene included on the CD qRT-PCR array were sourced from two public PCR primer databases (RTPrimerDB 26 and PrimerBank
27
). For genes that were not listed in these databases or demonstrated to be unsuitable for qPCR, relevant primers were designed and tested to determine MIQE compliance and were synthesized by either Geneworks (Thebarton, SA, Australia) or Sigma Aldrich (Castle Hill, NSW, Australia).
The qPCR reactions were performed using 10 ng of cDNA from healthy control subjects and patients with CD on 384-well plates with four patient samples on each plate and amplified using SSOAdvanced Universal SYBR Green Supermix (BioRad, USA) in a CFX96 Touch Real-Time PCR cycler (BioRad, USA) using the following program. 28 was used to select reference genes for the CD qRT-PCR array by screening 10 ng of cDNA from three representative healthy control subjects and three CD patients. Finally, a 108 bp fragment of HTR4 was used as the inter-plate calibrator gene.
Immunohistochemical analysis. Immunohistochemical analysis of four differentially expressed genes (CD203c, CD19, IL18, and IFNG) and IL17A, which was differentially expressed in treated biopsies, was performed to verify the gene expression data. Biopsy sections were deparaffinized in Solv21C with 2 × 10 min washes and rehydrated in decreasing concentrations of ethanol (100%, 95%, and 80%) before rinsing in tap water and antigen retrieval (Target Retrieval Solution [pH 6; Dako/Agilent Technologies, Denmark]) for 30 min at 95°C. Slides were rinsed in tap water and rinsed twice with phosphate-buffered saline, 1% w/v bovine serum albumin and 2% fetal calf serum. Slides were incubated with fluorescent antibodies (Table 2) for 1 h at room Please note patients TF6 and TM1 provided two biopsies to this current study, one at their initial diagnosis and one after the specified amount of time on a treatment program. This allowed for the visualization of the treatment progression for these two patients. The other treated CD patients in this study were diagnosed before the commencement on the study and thus did not provide an initial biopsy sample.
temperature. Slides were washed with wash buffer (phosphatebuffered saline/0.05% Tween-20) before counterstaining with DAPI and mounted using Vectashield H-1000 Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Slides were visualized using a Zeiss Axio Imager 2 microscope, and image acquisition and analysis were performed using Axiovision software (version 4; Carl Zeiss Microscopy, Birkerød, Denmark). IL18 and IFNG (Table 2) immunohistochemistry was developed using a DAB secondary antibody detection kit (Abcam, UK). Slides were prepared as described previously except before primary antibody staining slides were incubated with H 2 O 2 in distilled water for 10 min at room temperature. The slides were rinsed with wash buffer and then incubated with a protein blocking solution for 10 min at room temperature and incubated with the primary antibody for 30 min at room temperature. The slides were rinsed with wash buffer before being incubated with a one-step HRP secondary antibody polymer (Abcam, Cambridge, UK) for 30 min at room temperature. Slides were then rinsed with wash buffer and distilled water, developed using DAB substrate for 5 min, and counterstained with Mayer's hematoxylin, dried, and mounted using DPX (Sigma Aldrich, Castle Hill, NSW, Australia). Image data were collected using an Olympus BX41 Confocal Microscope with Olympus DP Controller Software (Olympus Corporation, Shinjuku, Tokyo, Japan).
Statistical analyses. Gene expression data were analyzed using CFX Manager Software version 3.1 (BioRad, USA). Firstly, quality control of the array was undertaken with the assessment of the integrity of the reference genes and inter-plate calibrator stability. To assess the distribution of the data, Kolmogorov-Smirnov testing was then performed using SPSS (v22.0, IBM, Armonk, NY, USA). All data were presented as fold changes unless stated otherwise. Because of the low sample numbers, an upper significance level of p < 0.06 was used to assess the statistical significance of the data. A Spearman's correlation analysis was performed to examine the relationships between the differentially expressed genes and Marsh score. Multivariate analysis of variance and principal component analysis were performed using SPSS to determine matrix variance of the differentially expressed genes. Gene expression discriminant analysis (StatistiXL v1.10; www.statistixl.com) was performed to determine equations used to classify Marsh score categories in CD patients.
Results
Defining the genes on the celiac disease quantitative reverse transcription-polymerase chain reaction array. Systematic analysis of transcriptomic data in the literature (Table 3) identified genes for inclusion in the CD qRT-PCR. A total of 50 626 genes were analyzed by these studies from a total of 2463 CD patient biopsies and 4881 healthy subjects. Five hundred seventy-three genes were significantly (P < 0.05) differentially expressed in CD when compared with healthy subjects. The differentially expressed genes were partitioned into immune responses and intestinal physiology pathways. Systematic review of the CD literature facilitated the inclusion of an additional 44 CD associated genes into the CD qRT-PCR array. Several genes associated with colitis and inflammatory bowel disease were also included in an attempt to distinguish CD from the other intestinal disorders. [29] [30] [31] [32] Therefore, the CD qRT-PCR array was composed of 87 genes of interest, four reference genes (GAPDH, ACTB, RPL13A, and SDHA), and an inter-plate calibrator. The mean Cq value for the inter-plate calibrator gene was determined to be 19.5 ± 0.36 indicating low plate-to-plate variation for the CD qRT-PCR array.
Celiac disease quantitative reverse transcriptionpolymerase chain reaction array gene expression. The qRT-PCR array was used to determine the gene expression associated with the various Marsh score grades of CD (Fig. 1) . Figure 1a demonstrated that only IL18 was significantly upregulated in Marsh type 1 CD when compared with Marsh type 0 CD. However, when Marsh type 1 CD was compared with Marsh type 3a CD, gene expression from a total of nine genes (including CD203c, IL18, IL15, and NPC1L1) were significantly upregulated. Eleven genes were shown to be significantly upregulated in Marsh type 1 CD when compared with Marsh type 3b CD, with the highest differences in the expression of CD203c, IL18, NR3C1, and NPC1L1 as well as ALPI and DEFA5.
Thirteen genes were significantly upregulated in Marsh type 3a CD when compared with Marsh type 0 tissue, with IFNG and CD19 showing eightfold and fourfold changes, respectively (Fig. 1b) . Comparison of Marsh 3a against Marsh type 1 CD revealed eight genes (including FGF7, CD326, and ACAT2) that were significantly upregulated. In contrast, two genes, ACAT2 and IL15, were upregulated in Marsh type 3a compared with Marsh type 3b, although their fold changes were minor.
Finally, Figure 1c shows the genes that were significantly differentially expressed between Marsh type 3b CD and the other Marsh score categories. When comparing Marsh type 3b CD to Marsh type 0 biopsies, six genes (CD19, CD203c, HLA-E, DEFA5, IFNG, and IL18) were significantly upregulated, with IFNG showing a 10-fold increase in Marsh 3b CD compared with normal duodenal tissues. Eleven genes (including TGM2, TAP1, and CD54) were significantly upregulated greater than twofold between Marsh type 3b compared with Marsh type 1 CD. To The genes were grouped into functional categories: SIC, specific immune cells; innate, innate immunity; adaptive, adaptive immunity; intestinal, markers associated with intestinal absorption and differentiation. Genes marked with * were shown to be statistically significant (p ≤ 0.06).
summarize, the Marsh score categories (M0, M1, and M3a and b) were stratified by the expression signatures of 26 genes.
Biopsy immunohistochemistry. Five of the differentially expressed genes (CD19, CD203c, IFNG, IL18 and IL17A) were validated using immunohistochemistry (Figs 2 and 3 ). CD19, a B cell marker, had minimal staining in healthy mucosal biopsies (Marsh score 0) indicating the presence of minimal numbers of CD19 positive B cells in the duodenal lamina propria (Figs 2a,b) . In contrast, higher numbers of CD19 positive B cells were present in Marsh type 3a mucosa. These data suggested that B lymphocytes were associated with Marsh Score 3a pathology and correlated with mRNA levels (Fig. 1) . CD203c, a basophil marker, was present within the lamina propria of the duodenum of Marsh score 1 biopsies (Fig. 2c) , whereas no CD203c positive cells were observed in the destructive lesions of active CD (M3b; Fig. 2d ). The immunofluorescence distribution of IL17A in healthy duodenal mucosa (Fig. 2e ) and Marsh type 3a CD (Fig. 2f ) and treated CD mucosa are shown (Fig. 2g) . Healthy mucosa did not express IL17A protein, whereas Marsh type 3a biopsies had very low numbers of IL17A positive cells. In contrast, some biopsies from treated patients were highly positive for IL17A protein.
In healthy duodenal tissue sections, there was an absence of diffuse extracellular and cell-associated IFNG staining (Fig. 3a) . In contrast, for Marsh score 3a biopsies, extracellular and cellassociated IFNG staining was present (Fig. 3b) . These results correlated strongly with the gene expression findings for IFNG (Fig. 1) . IL18 immunohistochemistry in patients with Marsh type 3a CD and Marsh type 1 CD indicated that only a small amount of IL18 was present in the Marsh type 3a lesion (Fig. 3d) . In Marsh score 1 mucosa however, there was a clear increase in the number of IL18 positive cells as well as extracellular IL18 within the lamina propria (Fig. 3c) . Thus, the immunohistochemical analysis of CD19, CD203c, IFNG, IL18, and IL17A confirmed the qRT-PCR gene expression data of these genes.
Marsh score classification equations. Differential gene expression data were used to define discriminant equations, which were then used to classify patient biopsies according to (Table 4 ). Figure 4 demonstrated that the gene expression-defined discriminant functions were able to resolve untreated CD and healthy subject biopsies into discrete Marsh score categories. Tight clustering of patients, with excellent separation of the Marsh score categories, was demonstrated by these functions. Function 2 was responsible for the separation of active CD (M3) from mild CD (M1) and normal duodenal biopsies. M0 (normal subjects) was most discriminated by CD19 and CD86. Patients in the M1 group were discriminated by TAP1. M3a patients were discriminated by HSPA1A, CD11c, DEFA5, and C5a, while M3b and M3c patients were discriminated by CD54, TGM2, and CD117 (Fig. 4) .
To test the classification accuracy of these predictive functions, a classification accuracy analysis was performed. Functions 1 and 2 correctly classified all biopsies into the Marsh score categories, which were previously defined by qualified pathologists. However, a more stringent holdout analysis was unable to be performed because of the small patient numbers. These same gene expression-based discriminant equations were also used to classify treated patient biopsies (Fig. 5) . The post-treatment only samples spanned a wider range than the Marsh score. However, the two before and after treatment samples demonstrated the trajectory of the post-treatment samples away from M3 and towards M0 and M1 categories, which agreed with the reported histopathology assessment of these biopsies.
Discussion
This study has defined a qRT-PCR array that was used to examine the gene expression patterns associated with Marsh score CD severity grades. The hypothesis that governed this study was that duodenal gene expression occurs before and underpins pathological duodenal morphological changes associated with CD Marsh score severity. As such, these gene expression changes may be Celiac disease diagnosis by Gene Expressionused to stratify duodenal biopsies into Marsh score categories of CD severity.
To construct the qRT-PCR CD array, it was necessary to perform a detailed systematic analysis of the previously published transcriptomic CD data. Of the 26 genes that were differentially expressed, 54% were identified by transcriptomics analysis, while 46% were identified from the CD literature. The ontology and magnitude of expression of the differentially expressed genes were associated with the various Marsh score grades. Less severe CD, as indicated by a lower Marsh score histological assessment were predominantly associated with innate immune response and intestinal structure and differentiation genes. For example, IL18, a potent innate immune system inflammatory mediator, 33, 34 was upregulated in mild (M1) CD compared with normal duodenal tissue. In contrast, biopsies from patients with more severe manifestations of CD expressed more inflammatory and adaptive immune response genes as well as perturbations in structural morphology genes.
Gene expression in the duodenum of patients with active CD (3a and b) were characterized by increased expression of immune cell marker genes (CD11b, CD19, CD117, and HLA-E). In addition, the expression of the cytokine marker IFNG was shown to be increased in Marsh type 3a biopsies when compared with Marsh type 0 tissue. Another cytokine marker, IL18, was shown to have reduced expression in Marsh type 3a tissue when compared with Marsh type 1 tissue at the protein level.
The increased expression of immune cell marker genes provided indirect evidence of the increased presence of infiltrated B cells, antigen presentation cells, and mast cells in the duodenum of patients with active CD, thereby confirming the finding that these cells were present in the duodenum of patient biopsies with active CD.
2,14,34-36 There were subtle differences in the genes expressed in biopsies identified as Marsh score 3a compared with 3b. Despite this, the Marsh score 3 subclassifications were resolved by the discriminant equations. Collectively, these data suggested that the differential expression of genes underpinned the morphological changes 14 associated with CD progression. Discriminant analysis has been used to successfully classify disease status in human [37] [38] [39] [40] [41] and veterinarian 42 medicine. In this study, gene expression data from biopsies were stratified into the discrete Marsh score categories and defined discriminant equations capable of classifying patient biopsies into their discrete Marsh score groups. When before and after treatment biopsies were classified, the post-treatment biopsies were positioned closer to the milder CD Marsh scores. Thus, it is tantalizing to speculate that because the equations defined by gene expression parameters were able to classify patients along the Marsh score scale that these type of equations may prove useful for classifying biopsies from equivocal cases. However, much larger sample sizes from each Marsh score cohort are required before this can be realized. In addition, before these equations can be used for the clinical diagnosis of CD severity, it must be demonstrated that these CD classification equations specifically identify and grade CD independently of other duodenal pathologies.
Finally, the advantages of using gene expression-derived equations to define CD severity are as follows: firstly, that these equations were able to successfully classify patient biopsies into discrete Marsh score categories. Secondly, the same biopsies taken from patients for histological assessment can be used for gene expression analysis using the CD qRT-PCR array defined by this study. Finally, because these gene expression-based equations can classify patient biopsies with high resolution into discrete Marsh score categories, they can potentially be used to classify cases with equivocal diagnoses, such as short-segment CD or non-CD duodenal inflammation and to monitor the treatment progress of patients. However, to progress this research, significantly more biopsies from all Marsh score categories are required to robustly define the classification equations. Secondly, the classification equations must be validated using a separate cohort of normal, untreated CD, and treated CD biopsy samples.
Nevertheless, this proof-of-concept pilot study successfully developed a CD qRT-PCR array and provided evidence that discriminant equations defined using gene expression data can accurately classify duodenal biopsies along the Marsh score scale. With growing acceptance of the limitations of CD small-intestinal histology, this study has also shown that the analysis of gene expression is a valid companion measure of mucosal inflammation and damage in CD. This study also raises the question whether the measurement of gene expression could improve the diagnostic accuracy of other intestinal pathologies, such as inflammatory bowel disease.
